spiro[cycloheptane-1,3'-indolin]-2'-one | 1377823-98-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: spiro[cycloheptane-1,3'-indolin]-2'-one
• 英文别名: spiro[1H-indole-3,1'-cycloheptane]-2-one
• CAS: 1377823-98-7
• 化学式: C₁₄H₁₇NO
• 分子量: 215.295
• InChiKey: IPUGCDZSBYETFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  在 盐酸 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 0.25h， 以0.043 g的产率得到spiro[cycloheptane-1,3'-indolin]-2'-one
  参考文献：
  名称：

  Asymmetric Pericyclic Cascade Approach to Spirocyclic Oxindoles

  摘要：

  The reaction of chiral N-arylnitrones with carbocyclic alkylarylketenes generates spirocyclic oxindoles in good yields and with excellent levels of enantioselectivity (90-99% ee) via a pericyclic cascade process.

  DOI：

  10.1021/ol300982f

文献信息

• Compositions and methods for inhibiting arginase activity
  申请人：CALITHERA BIOSCIENCES, INC.

  公开号：US10597411B2

  公开（公告）日：2020-03-24

  The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.

  本公开涉及一类对精氨酸酶具有活性抑制作用的新型化合物，以及包含本公开化合物的药物组合物。本文还提供了使用本公开的精氨酸酶抑制剂治疗癌症的方法。
• COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
  申请人：CALITHERA BIOSCIENCES, INC.

  公开号：US20190330244A1

  公开（公告）日：2019-10-31

  The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
• [EN] CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF<br/>[FR] INHIBITEURS DE CD73 ET LEURS UTILISATIONS PHARMACEUTIQUES
  申请人：[en]RISEN (SUZHOU) PHARMA TECH CO., LTD.

  公开号：WO2022109741A1

  公开（公告）日：2022-06-02

  CD73 (also known as ecto-5´-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I': (I') and pharmaceutically acceptable esters or salts thereof.